160 related articles for article (PubMed ID: 27660691)
1. Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design.
Jones SB; Pfeifer LA; Bleisch TJ; Beauchamp TJ; Durbin JD; Klimkowski VJ; Hughes NE; Rito CJ; Dao Y; Gruber JM; Bui H; Chambers MG; Chandrasekhar S; Lin C; McCann DJ; Mudra DR; Oskins JL; Swearingen CA; Thirunavukkarasu K; Norman BH
ACS Med Chem Lett; 2016 Sep; 7(9):857-61. PubMed ID: 27660691
[TBL] [Abstract][Full Text] [Related]
2. Identification and pharmacological characterization of a novel inhibitor of autotaxin in rodent models of joint pain.
Thirunavukkarasu K; Swearingen CA; Oskins JL; Lin C; Bui HH; Jones SB; Pfeifer LA; Norman BH; Mitchell PG; Chambers MG
Osteoarthritis Cartilage; 2017 Jun; 25(6):935-942. PubMed ID: 27638130
[TBL] [Abstract][Full Text] [Related]
3. Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo.
Kuttruff CA; Ferrara M; Bretschneider T; Hoerer S; Handschuh S; Nosse B; Romig H; Nicklin P; Roth GJ
ACS Med Chem Lett; 2017 Dec; 8(12):1252-1257. PubMed ID: 29259743
[TBL] [Abstract][Full Text] [Related]
4. "Hit" to lead optimization and chemoinformatic studies for a new series of Autotaxin inhibitors.
Stylianaki EA; Magkrioti C; Ladopoulou EM; Papavasileiou KD; Lagarias P; Melagraki G; Samiotaki M; Panayotou G; Dedos SG; Afantitis A; Aidinis V; Matralis AN
Eur J Med Chem; 2023 Mar; 249():115130. PubMed ID: 36702053
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Characterization of a Potent Inhibitor of Autotaxin in Animal Models of Inflammatory Bowel Disease and Multiple Sclerosis.
Thirunavukkarasu K; Tan B; Swearingen CA; Rocha G; Bui HH; McCann DJ; Jones SB; Norman BH; Pfeifer LA; Saha JK
J Pharmacol Exp Ther; 2016 Oct; 359(1):207-14. PubMed ID: 27516465
[TBL] [Abstract][Full Text] [Related]
6. Dendrimer Conjugate of [4-(Tetradecanoylamino)benzyl]phosphonic Acid (S32826) as an Autotaxin Inhibitor.
Fisher N; Hilton-Bolt T; Edwards MG; Haxton KJ; McKenzie M; Allin SM; Richardson A
ACS Med Chem Lett; 2014 Jan; 5(1):34-9. PubMed ID: 24900771
[TBL] [Abstract][Full Text] [Related]
7. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.
Gierse J; Thorarensen A; Beltey K; Bradshaw-Pierce E; Cortes-Burgos L; Hall T; Johnston A; Murphy M; Nemirovskiy O; Ogawa S; Pegg L; Pelc M; Prinsen M; Schnute M; Wendling J; Wene S; Weinberg R; Wittwer A; Zweifel B; Masferrer J
J Pharmacol Exp Ther; 2010 Jul; 334(1):310-7. PubMed ID: 20392816
[TBL] [Abstract][Full Text] [Related]
8. Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain.
Inoue M; Ma L; Aoki J; Chun J; Ueda H
Mol Pain; 2008 Feb; 4():6. PubMed ID: 18261210
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, Characterization, and
Hunziker D; Reinehr S; Palmhof M; Wagner N; Biniasch T; Stute G; Mattei P; Schmitz P; DiGiorgio P; Hert J; Rudolph MG; Benz J; Stihle M; Gsell B; Müller S; Gasser R; Schonhoven N; Ullmer C; Joachim SC
Front Pharmacol; 2021; 12():699535. PubMed ID: 35126098
[TBL] [Abstract][Full Text] [Related]
10. Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry.
Cuozzo JW; Clark MA; Keefe AD; Kohlmann A; Mulvihill M; Ni H; Renzetti LM; Resnicow DI; Ruebsam F; Sigel EA; Thomson HA; Wang C; Xie Z; Zhang Y
J Med Chem; 2020 Jul; 63(14):7840-7856. PubMed ID: 32584034
[TBL] [Abstract][Full Text] [Related]
11. Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe.
Kawaguchi M; Okabe T; Okudaira S; Nishimasu H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
ACS Chem Biol; 2013 Aug; 8(8):1713-21. PubMed ID: 23688339
[TBL] [Abstract][Full Text] [Related]
12. Development of autotaxin inhibitors: A series of zinc binding triazoles.
Thomson CG; Le Grand D; Dowling M; Brocklehurst CE; Chinn C; Elphick L; Faller M; Freeman M; Furminger V; Gasser C; Hamadi A; Hardaker E; Head V; Hill JC; Janus DI; Pearce D; Poulaud AS; Stanley E; Sviridenko L
Bioorg Med Chem Lett; 2018 Jul; 28(13):2279-2284. PubMed ID: 29798825
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent inhibitors of the lysophospholipase autotaxin.
Shah P; Cheasty A; Foxton C; Raynham T; Farooq M; Gutierrez IF; Lejeune A; Pritchard M; Turnbull A; Pang L; Owen P; Boyd S; Stowell A; Jordan A; Hamilton NM; Hitchin JR; Stockley M; MacDonald E; Quesada MJ; Trivier E; Skeete J; Ovaa H; Moolenaar WH; Ryder H
Bioorg Med Chem Lett; 2016 Nov; 26(22):5403-5410. PubMed ID: 27780639
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Potent Selective Nonzinc Binding Autotaxin Inhibitor BIO-32546.
Ma B; Zhang L; Sun L; Xin Z; Kumaravel G; Marcotte D; Chodaparambil JV; Wang Q; Wehr A; Jing J; Hong VS; Wang T; Huang C; Shao Z; Mi S
ACS Med Chem Lett; 2021 Jul; 12(7):1124-1129. PubMed ID: 34267882
[TBL] [Abstract][Full Text] [Related]
15. Development of autotaxin inhibitors: A series of tetrazole cinnamides.
Thomson CG; Le Grand D; Dowling M; Beattie D; Elphick L; Faller M; Freeman M; Hardaker E; Head V; Hemmig R; Hill J; Lister A; Pascoe D; Rieffel S; Shrestha B; Steward O; Zink F
Bioorg Med Chem Lett; 2021 Jan; 31():127663. PubMed ID: 33160025
[TBL] [Abstract][Full Text] [Related]
16. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool.
Ferry G; Moulharat N; Pradère JP; Desos P; Try A; Genton A; Giganti A; Beucher-Gaudin M; Lonchampt M; Bertrand M; Saulnier-Blache JS; Tucker GC; Cordi A; Boutin JA
J Pharmacol Exp Ther; 2008 Dec; 327(3):809-19. PubMed ID: 18755937
[TBL] [Abstract][Full Text] [Related]
17. Disrupted Blood-Brain Barrier and Mitochondrial Impairment by Autotaxin-Lysophosphatidic Acid Axis in Postischemic Stroke.
Bhattarai S; Sharma S; Ara H; Subedi U; Sun G; Li C; Bhuiyan MS; Kevil C; Armstrong WP; Minvielle MT; Miriyala S; Panchatcharam M
J Am Heart Assoc; 2021 Sep; 10(18):e021511. PubMed ID: 34514847
[TBL] [Abstract][Full Text] [Related]
18. Identification and structure-activity relationship studies of small molecule inhibitors of the human cathepsin D.
Goyal S; Patel KV; Nagare Y; Raykar DB; Raikar SS; Dolas A; Khurana P; Cyriac R; Sarak S; Gangar M; Agarwal AK; Kulkarni A
Bioorg Med Chem; 2021 Jan; 29():115879. PubMed ID: 33271453
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
Federico L; Pamuklar Z; Smyth SS; Morris AJ
Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
[TBL] [Abstract][Full Text] [Related]
20. Identification of Potent
Kawaguchi M; Okabe T; Okudaira S; Hama K; Kano K; Nishimasu H; Nakagawa H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
J Med Chem; 2020 Mar; 63(6):3188-3204. PubMed ID: 32134652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
